A PHASE III, RANDOMISED, OPEN, CONTROLLED, MULTICENTRE, PRIMARY VACCINATION STUDY TO EVALUATE THE IMMUNOGENICITY AND PERSISTENCE OF 1 AND 2 DOSES OF MENINGOCOCCAL CONJUGATE VACCINE MENACWY-TT IN TODDLERS (AFTER 1 MONTH AND UP TO 5 YEARS) AND TO DEMONSTRATE NON-INFERIORITY OF CO-ADMINISTRATION OF MENACWY-TT AND 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE PREVENAR 13(REGISTERED) VERSUS SEPARATE ADMINISTRATION OF THE 2 VACCINES
Latest Information Update: 12 Jan 2023
Price :
$35 *
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Meningococcal infections; Pneumococcal infections
- Focus Pharmacodynamics; Registrational
- Acronyms MENACWY-TT-104
- Sponsors GlaxoSmithKline; GSK; Pfizer
- 06 Jan 2023 Results published in the Vaccine
- 08 Jun 2020 Status changed from active, no longer recruiting to completed.
- 24 Feb 2020 This trial is completed inCzech Republic (GlobalEnd Date: 5 Dec 2019), according to European Clinical Trials Database record.